Clinical trial
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
NCT00442533 · Radio Isotope Therapy of America, Other · Completed
Key facts
| NCT number | NCT00442533 |
|---|---|
| Title | Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors |
| Official title | High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms. |
| Lead sponsor | Radio Isotope Therapy of America, Other |
| Collaborators | Excel Diagnostic Imaging Clinics Radiomedix, Inc. Industry CHI St. Luke's Health, Texas |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Neuroendocrine Tumors |
| Intervention type | Drug |
| Interventions | Indium-111 pentetreotide |
| Enrollment | 200 |
| Start date | Aug 1, 2005 |
| Primary completion | Aug 30, 2014 |
| Completion | Dec 28, 2015 |
| First posted | Mar 2, 2007 |
| Last update posted | Apr 3, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: